Kaveri Pohlman
Stock Analyst at Clear Street
(4.31)
# 1,341
Out of 4,534 analysts
233
Total ratings
41.3%
Success rate
11.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kaveri Pohlman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVMN Evommune | Maintained: Buy | $28 | $11.53 | +142.84% | 3 | Jul 16, 2026 | |
| MLTX MoonLake Immunotherapeutics | Maintained: Buy | $70 | $19.05 | +267.45% | 6 | Jun 22, 2026 | |
| CGEM Cullinan Therapeutics | Maintained: Buy | $33 → $46 | $17.50 | +162.86% | 19 | Jun 10, 2026 | |
| LBRX LB Pharmaceuticals | Initiated Coverage: Buy | $45 | $30.90 | +45.63% | 1 | May 26, 2026 | |
| SGMT Sagimet Biosciences | Maintained: Buy | $37 → $28 | $7.16 | +291.06% | 4 | May 13, 2026 | |
| TRVI Trevi Therapeutics | Maintained: Buy | $21 → $29 | $16.77 | +72.93% | 3 | May 7, 2026 | |
| MDGL Madrigal Pharmaceuticals | Maintained: Buy | $533 → $680 | $535.69 | +26.94% | 3 | May 6, 2026 | |
| ORKA Oruka Therapeutics | Maintained: Buy | $71 → $131 | $91.71 | +42.84% | 4 | Apr 27, 2026 | |
| ELVN Enliven Therapeutics | Maintained: Buy | $36 → $55 | $51.67 | +6.44% | 2 | Apr 27, 2026 | |
| PTGX Protagonist Therapeutics | Maintained: Buy | $104 → $116 | $134.27 | -13.61% | 5 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $1.91 | +528.27% | 2 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $11 → $20 | $18.82 | +6.27% | 3 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $200 → $220 | $124.15 | +77.20% | 3 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $32 → $12 | $16.05 | -25.23% | 4 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $9.23 | +95.02% | 1 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $61 → $99 | $46.98 | +110.73% | 2 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $25 | $19.67 | +27.10% | 2 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $5.26 | +242.21% | 2 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $6.26 | +91.69% | 17 | Nov 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $32 → $47 | $28.22 | +66.55% | 2 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $55.53 | n/a | 8 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $4.32 | n/a | 16 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $18.81 | n/a | 13 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $28.17 | n/a | 30 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $27.91 | n/a | 18 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $10.51 | n/a | 13 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $6.82 | n/a | 16 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.25 | n/a | 4 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $13 | $3.70 | n/a | 17 | Jun 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $21 | $1.99 | n/a | 1 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.0001 | n/a | 6 | Nov 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $16 → $8 | $3.52 | n/a | 3 | Jul 6, 2022 |
Evommune
Jul 16, 2026
Maintained: Buy
Price Target: $28
Current: $11.53
Upside: +142.84%
MoonLake Immunotherapeutics
Jun 22, 2026
Maintained: Buy
Price Target: $70
Current: $19.05
Upside: +267.45%
Cullinan Therapeutics
Jun 10, 2026
Maintained: Buy
Price Target: $33 → $46
Current: $17.50
Upside: +162.86%
LB Pharmaceuticals
May 26, 2026
Initiated Coverage: Buy
Price Target: $45
Current: $30.90
Upside: +45.63%
Sagimet Biosciences
May 13, 2026
Maintained: Buy
Price Target: $37 → $28
Current: $7.16
Upside: +291.06%
Trevi Therapeutics
May 7, 2026
Maintained: Buy
Price Target: $21 → $29
Current: $16.77
Upside: +72.93%
Madrigal Pharmaceuticals
May 6, 2026
Maintained: Buy
Price Target: $533 → $680
Current: $535.69
Upside: +26.94%
Oruka Therapeutics
Apr 27, 2026
Maintained: Buy
Price Target: $71 → $131
Current: $91.71
Upside: +42.84%
Enliven Therapeutics
Apr 27, 2026
Maintained: Buy
Price Target: $36 → $55
Current: $51.67
Upside: +6.44%
Protagonist Therapeutics
Apr 6, 2026
Maintained: Buy
Price Target: $104 → $116
Current: $134.27
Upside: -13.61%
Mar 31, 2026
Maintained: Buy
Price Target: $12
Current: $1.91
Upside: +528.27%
Mar 6, 2026
Rated: Buy
Price Target: $11 → $20
Current: $18.82
Upside: +6.27%
Mar 2, 2026
Maintained: Buy
Price Target: $200 → $220
Current: $124.15
Upside: +77.20%
Jan 20, 2026
Downgraded: Hold
Price Target: $32 → $12
Current: $16.05
Upside: -25.23%
Dec 11, 2025
Reiterated: Buy
Price Target: $18
Current: $9.23
Upside: +95.02%
Dec 9, 2025
Maintained: Buy
Price Target: $61 → $99
Current: $46.98
Upside: +110.73%
Dec 1, 2025
Maintained: Buy
Price Target: $25
Current: $19.67
Upside: +27.10%
Dec 1, 2025
Maintained: Buy
Price Target: $18
Current: $5.26
Upside: +242.21%
Nov 26, 2025
Maintained: Buy
Price Target: $12
Current: $6.26
Upside: +91.69%
Nov 11, 2025
Maintained: Buy
Price Target: $32 → $47
Current: $28.22
Upside: +66.55%
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $55.53
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $4.32
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $18.81
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $28.17
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $27.91
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $10.51
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $6.82
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $2.25
Upside: n/a
Jun 2, 2024
Maintained: Buy
Price Target: $13
Current: $3.70
Upside: n/a
Apr 29, 2024
Maintained: Buy
Price Target: $21
Current: $1.99
Upside: n/a
Nov 23, 2022
Downgraded: Hold
Price Target: n/a
Current: $0.0001
Upside: n/a
Jul 6, 2022
Rated: Buy
Price Target: $16 → $8
Current: $3.52
Upside: n/a